Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sun Pharmaceutical Industries announced Q2FY26 results Sales at Rs 1,44,052 million, a growth of 8.6%. Global Innovative Medicines sales stood at USD 333 million, up 16.4% and accounting for 20.2% of sales. EBITDA was Rs 45,271 million, up 14.9%. EBITDA margin was 31.3%. Profit before exceptional items and tax was Rs 41,676 million, up 15.8%. Net profit was Rs 31,180 million, up 2.6%. R&D; investment was Rs 7,827 million or 5.4% of sales. Kirti Ganorkar, Managing Director, said: “India, Emerging Markets and Rest of World led our growth for the period. US sales of Innovative Medicines have surpassed Generics for the first time during the quarter. We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability.” Result PDF
